Page last updated: 2024-12-05

erythropoietin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Erythropoietin (EPO) is a hormone primarily produced by the kidneys in response to low oxygen levels in the blood. It stimulates the production of red blood cells (erythrocytes) in the bone marrow. EPO is a glycoprotein that binds to receptors on erythroid progenitor cells, promoting their proliferation and differentiation into mature red blood cells. EPO plays a crucial role in maintaining oxygen-carrying capacity in the blood. It is studied extensively for its therapeutic potential in treating anemia, particularly in patients with chronic kidney disease. EPO is also used in athletes to enhance performance, but this practice is prohibited as it is considered doping. EPO's importance lies in its ability to regulate red blood cell production, ensuring adequate oxygen delivery to tissues. It is synthesized in the kidneys and released into the bloodstream. EPO has various effects, including stimulating erythropoiesis, increasing red blood cell count, and improving oxygen transport. EPO research focuses on its use in treating anemia, understanding its role in various physiological processes, and developing new therapies.'

1,5-dinitronaphthalene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,5-dinitronaphthalene : A dinitronaphthalene carrying nitro groups at positions 1 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11803
CHEMBL ID167316
CHEBI ID50640
SCHEMBL ID57166
MeSH IDM0007726

Synonyms (47)

Synonym
unii-ui2s14iw4t
ui2s14iw4t ,
AKOS002380303
naphthalene, 1,5(or 1,8)-dinitro-
einecs 248-484-4
naphthalene, dinitro-
nsc20593
nsc-20593
1,5-dinitronaphthalene
605-71-0
inchi=1/c10h6n2o4/c13-11(14)9-5-1-3-7-8(9)4-2-6-10(7)12(15)16/h1-6
naphthalene, 1,5-dinitro-
NCGC00090841-01
brn 0527184
einecs 210-095-2
ccris 6028
napththalene, 1,5-dinitro-
nsc 20593
ai3-08910
1,5-dinitronaphthalene, >=97.0% (hplc)
CHEBI:50640 ,
D0836
MLS002415672
smr001370870
1,5-dinitro-naphthalene
CHEMBL167316
A832792
NCGC00090841-02
HMS3039G05
dtxcid505165
NCGC00258506-01
dtxsid4025165 ,
tox21_200953
cas-605-71-0
71607-49-3
einecs 275-690-1
1,5(or 1,8)-dinitronaphthalene
SCHEMBL57166
1,5-dinitro naphthalene
W-105245
dinitronaphthalene, 1,5-
AC-29183
mfcd00003916
1,5-dinitronaphthalene 10 microg/ml in cyclohexane
Q27122162
AS-17821
EN300-88412
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dinitronaphthalene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency3.16230.004023.8416100.0000AID485290
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.61440.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency3.26430.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency48.67220.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.80030.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.01540.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency77.35030.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency6.95480.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.54520.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.71540.000229.305416,493.5996AID1259244; AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
aryl hydrocarbon receptorHomo sapiens (human)Potency15.43340.000723.06741,258.9301AID743122
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency31.81380.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency14.12540.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.93850.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.93850.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's5 (38.46)29.6817
2010's6 (46.15)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 114.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index114.00 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index201.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (114.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]